Kanwa Bio: ACYW135 Meningococcal Conjugate Vaccine Approved for Clinical Trials.

Kanghua Biological announced that the ACYW135 meningococcal conjugate vaccine developed by the company has obtained the Drug Clinical Trial Approval Notice from the National Medical Products Administration, allowing it to conduct clinical trials for the prevention of epidemic meningitis caused by groups A, C, Y, and W135 meningococcal strains. The vaccine covers the main pathogenic serogroups and is intended for use in individuals aged 2 months and older. The approval will not have a significant impact on the company's short-term finances or performance. If the research and development is successful and the vaccine is launched, it will enrich the product pipeline and enhance core competitiveness. However, there are uncertainties in vaccine development, and the company will disclose progress in a timely manner.